YORK, Pa., March 29, 2011 /PRNewswire/ — Unilife
Corporation (“Unilife” or the “Company”) (Nasdaq:
UNIS; ASX: UNS) today announced it has commenced initial
production of the Unifill® ready-to-fill (prefilled) syringe at
its FDA-registered manufacturing facility in York,
Pennsylvania.
The initial production of the Unifill syringe, the world’s first
prefilled syringe with safety features fully integrated within the
glass barrel, will enable Unilife to further accelerate discussions
with more than 20 pharmaceutical companies. These pharmaceutical
companies are at various stages of review in the potential use of
the Unifill syringe with a number of approved and pipeline
injectable drugs and vaccines across more than a dozen therapeutic
classes.
Once Unilife completes final product validation activities for
the Unifill syringe during the second quarter of 2011, the Company
can begin to fulfill initial sales orders to its existing
pharmaceutical partner. The supply and sale of the Unifill syringe
to other interested pharmaceutical companies is expected to
commence shortly afterwards.
Initial production batches are expected to be utilized by
pharmaceutical companies and contract manufacturing organizations
(which fill prefilled syringes with injectable drugs on behalf of
their pharmaceutical clients) for a number of activities.
This will include the initiation of drug stability studies,
market evaluations, and validating the integration of the product
into fill-finish systems currently used to load a measured dose of
an injectable drug or vaccine into equivalent standard prefilled
syringes.
Mr. Alan Shortall, CEO of Unilife, said, “We look forward to
being in a position to begin fulfilling initial sales orders for
the Unifill syringe towards the end of June, and consolidating
relationships with a number of interested pharmaceutical
compani
‘/>”/>
